CN111249381A - Application of composition in preparation of medicine for preventing and treating constipation - Google Patents
Application of composition in preparation of medicine for preventing and treating constipation Download PDFInfo
- Publication number
- CN111249381A CN111249381A CN202010232678.8A CN202010232678A CN111249381A CN 111249381 A CN111249381 A CN 111249381A CN 202010232678 A CN202010232678 A CN 202010232678A CN 111249381 A CN111249381 A CN 111249381A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- constipation
- group
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Abstract
The invention belongs to the field of medicines, and relates to medical application of a composition. In order to solve the problem of constipation caused by taking analgesics by cancer patients, the invention provides the application of a composition in preparing a medicine for preventing and treating constipation. Pharmacodynamic example results of mouse intestinal transit test show that: the composition provided by the invention can obviously improve the carbon juice propulsion rate of the small intestine of a mouse; the results of the mouse defecation test show that: the composition provided by the invention can obviously shorten the first defecation time of a mouse and increase the defecation frequency. Clinical results show that: the effective components in the composition can play a remarkable synergistic effect, can remarkably reduce the recurrence rate, and has important significance for solving the problem of constipation of cancer patients.
Description
Technical Field
The invention belongs to the field of medicines, relates to a medical application of a composition, and particularly relates to an application of the composition in preparation of a medicine for preventing and treating constipation.
Background
Constipation is one of the most common chronic digestive tract symptoms in clinic, the incidence rate in China is about 10% -15%, and the number of constipation people currently exceeds 1.3 hundred million. The domestic constipation survey data show that the incidence rate of constipation is related to factors such as age, sex, region, occupation, cultural degree and the like. Along with the improvement of living standard and the change of eating habits of people, the age of constipation patients is gradually advancing to the young development, and the constipation incidence rate in cities is far higher than that in rural areas. Research data show that aging is a high incidence factor of constipation, and patients with constipation increase significantly with age. The constipation is a disease which causes pain and embarrassment for people, most of traditional medicines for treating the constipation contain ingredients with purgation effect, strong dependence can be generated after long-term taking, and secondary constipation is easy to form, so the medicines are not suitable for long-term taking. People tend to select products which are purely natural, green, small in side effect and good in effect.
Opioid drugs, as analgesic drugs for moderately severe cancers, often cause severe constipation symptoms, the incidence rate is higher than 90%, and the quality of life of patients is seriously reduced. Firstly, the patients with constipation can not remove the endotoxin in the body in time, so that endorphin transmitters are increased, and the pain of the patients is enhanced; in addition, long-term constipation can paralyze intestinal tracts, cause serious intestinal obstruction and endanger life, so that timely and effective treatment of constipation is particularly important. However, the existing drugs for treating constipation all have the defects of different degrees and various side effects, and how to search for an efficient and healthy drug for treating constipation is particularly important for relieving the side effect of constipation caused by opioid drugs and improving the life quality of cancer patients.
Disclosure of Invention
In order to solve the above problems, the present invention provides a composition having a preventive and therapeutic effect on constipation.
The traditional Chinese medicine considers that the onset of constipation is in the large intestine, but is closely related to the viscera such as the liver, the spleen, the kidney and the like, the clinical classification standard generally comprises four types of heat constipation, qi constipation, deficiency constipation and cold constipation, and the traditional Chinese medicine considers that the treatment of the constipation is based on the principles of purging heat, guiding qi downward, guiding stagnation, invigorating qi, nourishing blood, moistening intestines, nourishing yin, warming yang and relaxing bowels, so that the treatment is performed by conditioning the viscera and dividing deficiency into excess and deficiency, the excess syndrome is mainly eliminated, the methods of purging heat, dispelling cold and regulating qi are respectively performed, and the product of guiding stagnation is supplemented; the deficiency syndrome is mainly treated by nourishing yin, nourishing blood, tonifying qi and warming yang according to the deficiency of yin, yang, qi and blood, and herbs with sweet and warm property for moistening intestines are used for treating both the symptoms and root causes. The composition provided by the invention contains the traditional Chinese medicine components of polygonum multiflorum, aloe, cassia seed, medlar, donkey-hide gelatin, ginseng, bighead atractylodes rhizome and immature bitter orange, wherein the polygonum multiflorum promotes gastrointestinal motility and has a mild diarrhea inducing effect, the aloe promotes gastrointestinal absorption and has anticancer activity, and the donkey-hide gelatin and the ginseng have a prescription for tonifying middle-jiao and qi, effectively treat the syndrome of deficiency of both qi and yin and accumulation of toxic factors, have the effects of purging turbid pathogen and relaxing bowels, nourishing yin and tonifying qi, and comprehensively improve the gastrointestinal function.
The specific technical scheme implemented by the invention is as follows:
pharmacodynamic example results of mouse intestinal transit test show that: the composition provided by the invention can obviously improve the carbon juice propulsion rate of the small intestine of a mouse; the results of the mouse defecation test show that: the composition provided by the invention can obviously shorten the first defecation time of a mouse and increase the defecation frequency. When the above effects are exerted, the components in the composition can exert remarkable synergistic effect.
Clinical examples the therapeutic effect of lactulose or hui laxative capsules alone and in combination on constipation caused by the administration of opioid analgesics was studied and the results showed: the combination can obviously increase the defecation frequency of a constipation patient, improve the clinical symptoms of the constipation patient, has obvious treatment effect on constipation, and can obviously reduce the recurrence rate of the constipation compared with the single use of lactulose or the aloe cathartic capsule. This clinical result indicates that: the combination of lactulose and the aloe laxative capsules can play a remarkable synergistic effect, and further shows that the components of the composition provided by the invention have a remarkable synergistic effect.
The composition comprises the following components in parts by weight: 60-150 parts of polygonum multiflorum, 200 parts of aloe 100-; preferably: 120 parts of polygonum multiflorum, 160 parts of aloe, 140 parts of cassia seed, 75 parts of medlar, 75 parts of donkey-hide gelatin, 50 parts of ginseng, 50 parts of bighead atractylodes rhizome, 120 parts of immature bitter orange and 8000 parts of lactulose.
The Chinese medicinal components in the composition are prepared from Polygoni Multiflori radix, Aloe, semen Cassiae, fructus Lycii, colla Corii Asini, Ginseng radix, Atractylodis rhizoma and fructus Aurantii Immaturus as raw materials.
The components and contents of the traditional Chinese medicine components in the composition are the same as those of the components and contents of the aloe-laxative capsule in the preparation process of the aloe-laxative capsule in patent 201811404355.1, and for convenience of description, the aloe-laxative composition is described in the embodiment, and for distinguishing the components, the composition provided by the invention is simply called the composition.
The composition provided by the invention can also contain pharmaceutically acceptable auxiliary materials, and the composition is prepared into a pharmaceutical preparation according to a conventional preparation process, such as: pill, tablet, granule, capsule, oral liquid, unguent, emulsion, chewable agent and injection.
Preferably tablets, capsules and granules.
When the preparation is applied to the prevention and treatment of constipation, the same treatment effect as the composition provided by the invention can be obtained.
The constipation described above is functional constipation, and is preferably functional constipation caused by a drug.
The drug is an analgesic, preferably an opioid analgesic.
The dosage of the composition for preventing and treating constipation is 3mg/kg.d-3000mg/kg.d, preferably 300 mg/kg.d.
Compared with the existing medicine for treating constipation, the composition provided by the invention has the following advantages:
1. the components of the composition have synergistic effect and obvious curative effect
The results of the efficacy examples and clinical examples show that: the traditional Chinese medicine components and lactulose in the composition provided by the invention can play a remarkable synergistic effect, remarkably increase the defecation frequency of a constipation patient and obviously improve clinical symptoms.
2. Reduce the recurrence rate
Clinical research results show that the combination of the two medicines can reduce the recurrence rate compared with the single lactulose and the aloe cathartic capsule, which shows that the composition provided by the invention can reduce the recurrence rate while exerting the synergistic effect among the components.
3. Has comprehensive and comprehensive effects
The composition provided by the invention not only can achieve the purpose of treating both principal and secondary aspects of constipation, but also can comprehensively condition the body of a cancer patient to achieve the effects of tonifying qi and replenishing qi.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present invention is further illustrated below by specific examples in order to provide those skilled in the art with a full understanding of the present invention, but it should be understood by those skilled in the art that the examples of the present invention are not to be construed as limiting the present invention in any way.
Examples of the drug action
1. Mouse small intestine propulsion test
60 healthy ICR mice are selected, the weight of each mouse is 18-22 g, the mice are randomly divided into 5 groups, and each group comprises 12 mice, namely a normal control group, a model control group, a hui cathartic composition group, a lactulose group and a composition group.
After the mice were fasted for 12 hours without water deprivation, loperamide hydrochloride (3.0mg/kg) was administered to each administration group except the normal control group by gavage, and the normal control group was administered with a corresponding volume of distilled water. After 30min, the administration groups respectively administrate drugs containing ink suspension (2% ink 100mL +1g sodium carboxymethylcellulose) with corresponding dose, and the normal control group and the model control group administrate ink suspension with corresponding volume, wherein the intragastric volume is 0.2mL/10 g.
Administration to each group of animals:
normal control group: intragastric administration of equal volume of distilled water
Model control group: intragastric administration of equal volume of distilled water
The aloe laxative composition comprises: the composition consisting of 8 Chinese medicinal components in the composition is administrated by intragastric administration, and the weight of the composition is 30mg/kg
Lactulose group: intragastric administration of lactulose, 3g/kg
Composition set (b): the composition provided by the invention is administrated by intragastric administration, 330 mg/kg
Killing the mice by cervical dislocation method 30min after administration, opening abdominal cavity to separate mesentery, cutting intestinal canal from pylorus, lower end to ileocecal part, measuring the length of the intestinal canal as "total length of small intestine", measuring the distance from pylorus to carbon juice advancing front as "carbon juice advancing length", and calculating carbon juice advancing rate. Carbon juice propulsion rate (%) = carbon juice propulsion length (cm)/total small intestine length (cm) × 100.
2. Mouse defecation test
60 healthy ICR mice are selected, the weight of each mouse is 18-22 g, the mice are randomly divided into 5 groups, and each group comprises 12 mice, namely a normal control group, a model control group, a hui cathartic composition group, a lactulose group and a composition group.
After the mice are fasted for 12h (water drinking is not limited) overnight, the administration groups except the normal control group are respectively administered with loperamide hydrochloride (3.0mg/kg) by gastric gavage, and the normal control group is administered with distilled water with corresponding volume. After 30min, the administration groups respectively administrate the medicines containing the corresponding dose of the ink suspension in the intragastric administration mode, and the normal control group and the model control group administrate the ink suspension with the corresponding volume, wherein the intragastric administration volume is 0.2mL/10 g.
Administration to each group of animals:
normal control group: intragastric administration of equal volume of distilled water
Model control group: intragastric administration of equal volume of distilled water
The aloe laxative composition comprises: the composition consisting of 8 Chinese medicinal components in the composition is administrated by intragastric administration, and the weight of the composition is 30mg/kg
Lactulose group: intragastric administration of lactulose, 3g/kg
Composition set (b): the composition provided by the invention is administrated by intragastric administration, 330 mg/kg
After administration, starting timing from administration of the ink suspension, each mouse is independently placed into a mouse cage with an interlayer (water absorption paper is laid on the bottom of the cage), water and food are normally drunk and eaten, the time of first discharging black feces of each mouse is observed and recorded, and the defecation times, weight and feces characters are observed and recorded within 6 hours.
3. Data processing
Data are expressed as mean ± standard deviation (' x + -s), and data analysis is performed by using SPSS15.0 statistical software. Two-sided t-test was used for significance analysis of differences between the two groups.
4. Results of the experiment
As can be seen from the results of table 1:
(1) the intestinal carbon juice propulsion rate of the model mice is obviously reduced compared with that of the normal control group (＃＃p is less than 0.01), indicating that the molding is successful.
(2) Compared with the model group, the intestinal carbon juice propulsion length of the lactulose group mouse is increased, but the propulsion rate has no significant difference compared with the model group; the aloe laxative composition group and the composition group provided by the invention have obviously increased intestinal carbon juice propulsion rate of mice (A)﹩p＜0.05 ，﹩﹩p < 0.01) and the composition provided by the invention has a significant difference in propulsion rate compared with a normal group (＃＃p＜0.01）。
The above results fully indicate that: the composition provided by the invention can obviously improve the intestinal carbon juice propulsion rate of mice, and the traditional Chinese medicine components and lactulose in the composition have obvious synergistic effect.
As can be seen from the results of table 2:
(1) compared with the normal group, the first defecation time of the model group is obviously prolonged, and the defecation times are obviously reduced (＃＃p is less than 0.01), which indicates that the molding is successful.
(2) The first defecation time of each administration group is obviously shortened compared with that of the model control group (﹩p＜0.05，﹩﹩p is less than 0.01, the defecation frequency is obviously increased (﹩﹩p＜0.01）。
The above results show that: the composition provided by the invention has a remarkable treatment effect on constipation of mice, and each component in the composition has a remarkable synergistic effect.
Clinical examples
1 data and method
1.1 general data
84 patients with the tumor of the aged cachexia who are collected from 2016 to 2018 in 8 are selected, all the patients are subjected to constipation caused by taking opioid analgesic drugs and are randomly divided into an observation group, a control 1 group and a control 2 group, and each group comprises 28 patients.
The inclusion standard of patients is ① age 60-80 years, ② meets Roman III standard of functional constipation, ③ patients have no communication disorder and are conscious, ④ survival period is more than 6 months, card type score is more than 50, and ⑤ all patients sign informed consent and are approved by ethical committee.
The exclusion standard is ① for organic diseases or operation history of tumor existing in abdomen and intestinal tract, ② patients with heart failure and liver and kidney function deficiency, ③ patients with severe cardiovascular and cerebrovascular diseases or diabetes, and ④ patients with drug allergy.
1.2 methods of treatment
Patients in each group normally take opioid drugs to relieve pain, and mainly take dietary fibers in the aspect of diet, so that more water is drunk, certain movement is kept, and long-term bed rest and other cathartic medicines are avoided. Control 1 group of oral lactulose oral liquid (the pharmaceutical company Suwei, the Netherlands) 15ml each time and 2 times a day for 2 weeks; control 2 oral Hui Tongbian capsules (Shuyishu, national Standard: Z20150041, Lu nan Qianpu pharmaceutical Co., Ltd.) 2 capsules at a time, 3 times daily for 2 weeks; the observation group takes lactulose and Aloe Vera cathartica capsules at the same time, and the frequency and dosage of taking medicine per day are the same as those of the group 1 and the group 2, and the treatment is continued for 2 weeks. The experiment is stopped for each group of patients with severe diarrhea during the treatment period, no obvious defecation sign appears after 5 days of treatment, and the patients are subjected to enema defecation treatment and do not participate in the experiment any more.
1.3 therapeutic efficacy determination
1.3.1 clinical efficacy determination
According to the standard of curative effect of diagnosis of traditional Chinese medicine diseases. The effect is shown: defecation is performed once within 2 days, the stool is moist and soft, the defecation is smooth, and abdominal distension does not exist; the method has the following advantages: the defecation is performed once within 3 days, the defecation tends to be soft, the defecation time is obviously shortened compared with that before treatment, and the abdominal distension symptom is obviously improved; and (4) invalidation: no improvement in symptoms; total effective rate = significant + effective.
1.3.2 clinical symptom score
Referring to the traditional Chinese medicine syndrome scoring table, it is shown in Table 3. Statistics is carried out on the self defecation frequency, the defecation difficulty degree, the abdominal pain, the abdominal distension and the defecation endless feeling before and after treatment of two groups of patients.
1.3.3 recurrence Rate statistics
The recurrence condition of the patients after the drug withdrawal for 4 weeks is counted.
1.4 statistical methods
Statistical analysis was performed on all experimental data using software SPSS19.0, all measurements represented as variances, using t-test, and counts using X2Examination of all comparison data P<0.05 is statistically significant.
2 results
2.1 clinical efficacy
The statistical results are shown in table 4, depending on the clinical signs of the patients. The total effective rate of the control group 1 is 57.1%, the total effective rate of the control group 2 is 60.7%, the total effective rate of the observation group is 96.4%, the total effective rate of the observation group is obviously higher than that of the control group 1 and the control group 2, and the ineffective rate of the observation group is obviously lower than that of the control group 1 and the control group 2. The clinical efficacy evaluation of the observation group is obviously better than that of the control group, and the difference has statistical significance (＃p＜0.05）。
The above results fully illustrate that: compared with the lactulose or the aloe cathartic capsule which is used singly, the combination can obtain better treatment effect, thereby further showing that the components of the composition provided by the invention have obvious synergistic effect when treating constipation.
2.2 clinical symptom score comparison
The results of evaluating clinical symptoms with reference to the syndrome scores of traditional Chinese medicine are shown in Table 5, from which it can be seen that each group of clinical symptoms before treatment is evaluatedDifferentiation without statistical significance (P)>0.05); the symptom scores of each group after treatment are obviously reduced compared with those before treatment, and the difference of each score before and after treatment has statistical significance (A)＃P<0.05); the scores of clinical symptoms of the observation groups after treatment are lower than those of the control group, and the difference has statistical significance (﹩P<0.05）。
2.3 comparison of relapses
The statistics of relapse conditions 4 weeks after drug withdrawal show that 3 cases exist in the control group 1, and the relapse rate is 10.7%; the relapse rate of 4 cases of the control group 2 is 14.3 percent; group 1 cases were observed, and the recurrence rate was only 3.5%.
Claims (10)
1. The composition is prepared from the raw materials of polygonum multiflorum, aloe, cassia seed, medlar, donkey-hide gelatin, ginseng, bighead atractylodes rhizome and immature bitter orange.
2. The use of claim 1, wherein the constipation is functional constipation.
3. The use of claim 2, wherein the functional constipation is drug induced functional constipation.
4. The use of claim 3, wherein the medicament is an analgesic.
5. The use of claim 4, wherein said analgesic is an opioid.
6. The use according to claim 1, wherein the composition comprises, in parts by weight: 60-150 parts of polygonum multiflorum, 200 parts of aloe 100-; more preferably, the traditional Chinese medicine composition comprises the following components in parts by weight: 120 parts of polygonum multiflorum, 160 parts of aloe, 140 parts of cassia seed, 75 parts of medlar, 75 parts of donkey-hide gelatin, 50 parts of ginseng, 50 parts of atractylodes macrocephala and 120 parts of immature bitter orange.
7. The use according to claim 1, wherein the composition may further comprise lactulose.
8. The use as claimed in claim 7, wherein the lactulose is present in an amount of 5000-10000 parts by weight; more preferably, 8000 parts by weight of lactulose.
9. The use of claims 1-7, wherein said composition can be formulated with pharmaceutically acceptable excipients into pharmaceutical formulations such as tablets, capsules, granules, and the like.
10. Use according to claim 1, wherein the composition is administered in a dose of 3mg/kg.d to 3000mg/kg.d, preferably 300mg/kg.d, for the prevention and treatment of constipation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010232678.8A CN111249381A (en) | 2020-03-28 | 2020-03-28 | Application of composition in preparation of medicine for preventing and treating constipation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010232678.8A CN111249381A (en) | 2020-03-28 | 2020-03-28 | Application of composition in preparation of medicine for preventing and treating constipation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111249381A true CN111249381A (en) | 2020-06-09 |
Family
ID=70946241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010232678.8A Pending CN111249381A (en) | 2020-03-28 | 2020-03-28 | Application of composition in preparation of medicine for preventing and treating constipation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111249381A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111643594A (en) * | 2020-07-28 | 2020-09-11 | 成都复兴医院有限公司 | Traditional Chinese medicine composition for treating opioid-related constipation, preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1748765A (en) * | 2004-09-17 | 2006-03-22 | 鲁南制药集团股份有限公司 | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method |
-
2020
- 2020-03-28 CN CN202010232678.8A patent/CN111249381A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1748765A (en) * | 2004-09-17 | 2006-03-22 | 鲁南制药集团股份有限公司 | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method |
Non-Patent Citations (2)
| Title |
|---|
| 健康之初: "专家提醒：阿片类药物引起的便秘，不容忽视！", pages 1 - 2, Retrieved from the Internet <URL:https://www.sohu.com/a/240572169_539814> * |
| 周佳宝等: "首荟通便胶囊治疗老年功能性便秘的疗效观察", 中国全科医学, vol. 22, no. 2, pages 149 - 151 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111643594A (en) * | 2020-07-28 | 2020-09-11 | 成都复兴医院有限公司 | Traditional Chinese medicine composition for treating opioid-related constipation, preparation method and application thereof |
| CN111643594B (en) * | 2020-07-28 | 2022-05-10 | 成都复兴医院有限公司 | Traditional Chinese medicine composition for treating opioid-related constipation, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102813801B (en) | Traditional Tibetan medicine for treating cough and preparation method thereof | |
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| CN110448629B (en) | Traditional Chinese medicine composition for treating constipation | |
| CN111249381A (en) | Application of composition in preparation of medicine for preventing and treating constipation | |
| CN110812417A (en) | Composition for treating constipation, preparation and application | |
| CN103191331B (en) | Traditional Chinese medicine composition for treating bronchial asthma in remission stage | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN102100744A (en) | Chinese medicine composition for treating mouth ulcer | |
| CN101732500A (en) | Medicine for preventing and treating acute and chronic pharyngitis and sphagitis | |
| CN110141619B (en) | Chinese herbal medicine composition for treating constipation and preparation method of gel patch thereof | |
| CN103285284A (en) | Medical composition for treating senile vaginitis | |
| TWI712417B (en) | Composition for moistening bowel and laxative and its application and functional food | |
| CN106038975A (en) | Traditional Chinese medicine composition having function of suppressing cough and preparation method and application of traditional Chinese medicine composition | |
| CN114917287B (en) | Traditional Chinese medicine composition for treating allergic asthma, preparation method and application thereof | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN104013708A (en) | Traditional Chinese medicine composition for oral administration to treat irritable bowel syndrome | |
| CN115624586B (en) | Traditional Chinese medicine composition for treating hormone-dependent asthma and application thereof | |
| CN114949147B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method and application thereof | |
| CN116350686B (en) | Medicinal and edible traditional Chinese medicine composition for treating dental ulcer and preparation method thereof | |
| CN116808110B (en) | Intestine-moistening and bowel-relaxing formula and preparation method thereof | |
| CN114569670B (en) | Traditional Chinese medicine composition for treating functional constipation of children | |
| CN116763880B (en) | Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation | |
| CN106728189B (en) | Traditional Chinese medicine for treating functional constipation of children and preparation method thereof | |
| CN100396299C (en) | Medication for treating astriction, and preparation method | |
| CN101361806B (en) | Traditional Chinese medicine formulation for treating gastrosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |